Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
phosphodiesterase 4 inhibitor |
| gptkbp:approvalYear |
2016
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:D11AH05
|
| gptkbp:brand |
gptkb:Eucrisa
|
| gptkbp:CASNumber |
gptkb:906673-24-3
|
| gptkbp:developer |
gptkb:Pfizer
gptkb:Anacor_Pharmaceuticals |
| gptkbp:form |
gptkb:hospital
|
| gptkbp:hasMolecularFormula |
C14H10BNO3
|
| https://www.w3.org/2000/01/rdf-schema#label |
crisaborole
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits phosphodiesterase 4 (PDE4)
|
| gptkbp:powers |
2%
|
| gptkbp:pregnancyCategory |
Not assigned
|
| gptkbp:routeOfAdministration |
topical
|
| gptkbp:sideEffect |
application site burning
application site pain |
| gptkbp:usedFor |
gptkb:eczema
gptkb:atopic_dermatitis |
| gptkbp:bfsParent |
gptkb:Anacor_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|